Skip to content

Novavax NVAX Other income, net (Note 6)

Other income, net (Note 6) at other companies

Vaxcyte, Inc. logo
Vaxcyte, Inc.PCVX
-$1.38M-119%
ALN
Alnylam PharmaceuticalsALNY
-$4.3M-147%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$336K-226%
Moderna logo
ModernaMRNA
Merck & Co. logo
Merck & Co.MRK
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Revenue$139.5M-79.1%
Gross profit$108.8M-83.3%
Operating income-$15.4M-103%
Net income-$9.5M-102%
EPS (diluted)-$0.06-102%

Balance sheet

See full
Cash & equivalents$228.4M-13.3%
Total debt$295.1M+404%
Total equity-$144.8M-91.4%
Total assets$1.0B-19.3%

Cash flow

See full
Operating cash flow-$32.4M+82.5%
CapEx$1.3M-20.4%
Free cash flow-$33.7M+82.0%

Valuation

See full
Market cap$1.46B+41.0%
Enterprise value$1.53B+83.6%
P/S2.5×+1.6×

Profitability

See full
Gross margin85%-2.5pp
Operating margin-13.1%-45.9pp
Net margin-14.7%-52.9pp
FCF margin-58.9%-61.4pp

Returns & leverage

See full
Return on equity-238.6%
Debt / equity1.5×
Current ratio2.5×+0.4×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Novavax's other income, net (note 6)?
Novavax (NVAX) reported other income, net (note 6) of $11.83M in Q1 2026.
How has Novavax's other income, net (note 6) changed year-over-year?
Novavax's other income, net (note 6) increased by 17.6% year-over-year, from $10.06M to $11.83M.
What is the long-term trend for Novavax's other income, net (note 6)?
Over 4 years (2021 to 2025), Novavax's other income, net (note 6) has grown at a 53.8% compound annual growth rate (CAGR), from -$7.27M to $40.63M.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.